EVERLAST-B Week 16 results showed 61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose group, highly consistent with EVERLAST-A

Oruka Therapeutics remains pre-revenue, with quarterly R&D expense rising from $18.7M in 2024Q2 to $53.7M in 2026Q3 and free cash outflow widening from -$2.6M to -$44.4M over the same span, suggesting clinical spend is accelerating faster than any operating scale.
Price trend, volume and key moving averages
Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 9, 2026 | -$0.63-5.1% vs -$0.60 | — vs — |
Q3 2026 Aug 10, 2026 | -$0.55-7.3% vs -$0.51 | — vs — |
Q2 2026 May 13, 2026 | -$0.48+12.2% vs -$0.55 | — vs — |
Q2 2026 Mar 12, 2026 | -$0.45+26.2% vs -$0.61 | — vs — |
EVERLAST-B Week 16 results showed 61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose group, highly consistent with EVERLAST-A

Candriam S.C.A. trimmed its holdings in Oruka Therapeutics, Inc. (NASDAQ: ORKA) by 3.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 339,032 shares of the company's stock after selling 13,684 shares during the period. Candriam S.C.A. owned about 0.51% of Oruka
MENLO PARK, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis and hidradenitis suppurativa, today announced its participation and presentation at multiple upcoming conferences: Guggenheim 3 rd Annual Healthcare Innovation Conference Date: November 10, 2026 Presentation Time: 11:00 AM EST Stifel 2026 Healthcare Conference Date: November 11, 2026 Presentation Time: 4:00 PM EST UBS Global Biopharma Conference Date: November 17, 2026 Presentation Time: 4:00 PM GMT Jefferies Global Healthcare Conference Date: November 18, 2026 Presentation Time: 4:30 PM GMT Webcasts and replays of Oruka's presentations will be available on the Oruka investor events website at https://ir.orukatx.com/news-events/events-presentations.
Oruka Therapeutics NASDAQ: ORKA reported interim week 16 results from EVERLAST-B, a Phase IIb dose-ranging study of ORKA-001 in adults with moderate-to-severe plaque psoriasis. The company said its 600-milligram regimen achieved complete skin clearance, measured by PASI 100, in 61% of participants at week 16, while 86% achieved PASI 90.
Benchmark ORKA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Oruka Therapeutics, Inc. (ORKA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $96.32 | $5.81B | -45.20 | — | — | -18.66% | — | |
| $957.76 | $98.67B | 20.99 | 0.99% | 28.51% | 15.07% | 0.36% | |
| $1.88 | $523.19M | -3.89 | — | — | -97.08% | — | |
| $27.33 | $3.42B | 125.02 | 91.34% | 5.88% | 14.18% | — | |
| $33.21 | $6.85B | -13.49 | — | -7173.52% | -63.01% | — | |
| $292.86 | $517.42B | 50.14 | 8.57% | 15.68% | — | 2.24% |
Oruka Therapeutics, Inc. (ORKA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when ORKA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Oruka Therapeutics, Inc. (ORKA) stock FAQ — growth, dividends, profitability & financials explained
No. Oruka Therapeutics, Inc. (ORKA) reported a net loss of $152.6M over the trailing twelve months.
Oruka Therapeutics, Inc. (ORKA) had a return on equity (ROE) of -18.7% over the trailing twelve months. A negative ROE means the company lost money over the period.
Oruka Therapeutics, Inc. (ORKA) had negative free cash flow of $123.9M over the trailing twelve months.